On Monday, Shares of ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS), gained 3.34% to $64.64.
Isis Pharmaceuticals, offered an update on children with spinal muscular atrophy (SMA) who have accomplished the open-label, Phase 2 multiple-dose study of ISIS-SMN and are ongoing to receive treatment in an open-label extension (OLE) study. Consistent with earlier observations, enhances in muscle function scores and additional motor function tests were observed in children treated with ISIS-SMN. Isis is presently collaborating with Biogen to develop and commercialize ISIS-SMN to treat patients with SMA.
“The natural course for children with untreated type II or type III SMA typically experience loss of muscle function that develops slowly and continually over time, a sustained enhance of three or more points in HMFSE scores represents a noteworthy departure from the natural course and is unusual for these children,” said Dr. Darryl De Vivo, Professor of Neurology and Pediatrics, Columbia University Medical Center.
Isis Pharmaceuticals, Inc. engages in the discovery and development of antisense drugs using novel drug discovery platform. The company’s flagship product comprises the KYNAMRO injection, which is an apo-B synthesis inhibitor for patients with homozygous familial hypercholesterolemia; and for the reduction of low-density lipoprotein cholesterol.
Shares of Diamond Offshore Drilling Inc (NYSE:DO), inclined 1.52% to $27.44, during its last trading session.
Diamond Offshore Drilling, declared that it will issue its future fleet status reports each calendar quarter concurrent with the release of its quarterly earnings. The Company has historically issued its fleet status reports on a monthly basis. The change from monthly to quarterly reporting is intended to better protect sensitive customer and contract information in light of competitive dynamics in the offshore drilling industry.
Diamond Offshore Drilling, Inc. provides contract drilling services to the energy industry worldwide. The company provides services in floater market, such as ultra-deepwater, deepwater, and mid-water; and non-floater or jack-up market.
At the end of Monday’s trade, Shares of Canadian Solar Inc. (NASDAQ:CSIQ), lost -0.87% to $ 32.03.
Canadian Solar Inc., declared that it held its 2015 Annual Meeting of Shareholders on June 22, 2015. Each of the proposals presented for shareholder approval was approved. Specifically, the shareholders approved:
- The election of Mr. Shawn (Xiaohua) Qu as a director of the Company;
- The election of Mr. Robert McDermott as a director of the Company;
- The election of Mr. Lars-Eric Johansson as a director of the Company;
- The election of Mr. Harry E. Ruda as a director of the Company;
- The election of Mr. Andrew (Luen Cheung) as a director of the Company; and
- The appointment of Deloitte Touche Tohmatsu Certified Public Accountants LLP as the auditors of the Company.
Canadian Solar Inc., together with its auxiliaries, designs, develops, manufactures, and sells solar wafers, cells, and solar power products worldwide. The company operates in two segments, Module and Energy.
Finally, Anthera Pharmaceuticals Inc (NASDAQ:ANTH), ended its last trade with 3.80% gain, and close at $9.56.
Anthera Pharmaceuticals, declared that it has met the enrollment target of its CHABLIS-SC1 Phase 3 clinical trial evaluating blisibimod for the treatment of lupus. Final data from the trial is predictable in the second half of 2016.
“Reaching our enrollment target for CHABLIS-SC1 ahead of plan is an important accomplishment,” said Dr. Colin Hislop, MD, Anthera’s Chief Medical Officer. “The accelerated pace speaks to the importance of patient identification and selection in lupus treatment. In addition, the wealth of new information released over the past year regarding the treatment of Systemic Lupus Erythematosus (SLE) and BAFF inhibition has demonstrated that patients with more severe disease, such as those enrolled in the CHABLIS-SC1 trial, are more likely to respond to a BAFF therapy. We look forward to the culmination of our efforts in CHABLIS-SC1 next year as we continue the development of blisibimod.”
Anthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing medicines for patients with unmet medical needs. It is developing blisibimod, a Phase III product candidate that targets B-cell activating factor associated with various B-cell mediated autoimmune diseases, counting systemic lupus erythematosus, Immunoglobulin A nephropathy, lupus nephritis, and others.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
